Pharmaceutical Composition Containing An Anti Parasitic Agent And Active Ingredient Selected From Carveol, Thymol, Eugenol, Borneol, Carvacrol, Alpha-Ionone, Or Beta-Ionone
AssigneeAdvanced Scientific Developments
InventorAdnane Remmal
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antiparasitic agent, in particular, an antimalarial agent. The invention is for use in the field of pharmaceutics.
Claims24
1-13. (canceled)
A pharmaceutical composition comprising:
- at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof, and
- at least one second therapeutically active substance which is an antiparasitic agent selected from the group consisting of antihelminthics, protozoacides and derivatives or mixtures thereof.
A kit comprising:
- at least one first container containing a first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof;
- and
- at least one second container containing a second therapeutically active substance which is an antiparasitic agent selected from the group consisting of salinomycin, artesunate, mefloquine, chloroquine, and derivatives or mixtures thereof.
A method for treating an infection caused by a parasite comprising simultaneously or sequentially administering to a patient having a parasitic infection:
- at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and isomers, derivatives or mixtures thereof, and
- at least one second therapeutically active substance which is an antiparasitic agent selected from the group consisting of salinomycin, artesunate, mefloquine, chloroquine, and derivatives or mixtures thereof.
Dependencies are inferred from the claim text.